ArticlePediatric health, medicine and therapeutics2026
A Case of Childhood Lupus Anticoagulant-Hypoprothrombinemia Syndrome with Diagnostic and Therapeutic Insight.
Article in Pediatric health, medicine and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is a rare coagulation disorder characterized predominantly by hemorrhagic manifestations. The laboratory findings of LAHPS are complex, including notably reduced prothrombin activity and a positive lupus anticoagulant test, making early recognition challenging. This article reports the diagnosis and treatment process of a pediatric LAHPS case, aiming to enhance clinicians' understanding and management of this disease. Materials and Methods: Clinical data and treatment details of the patient were retrospectively collected. A literature search was performed using the keywords "lupus anticoagulant", "LAHPS", and "PIVKA-II" in the PubMed database to retrieve evidence supporting clinical decision-making. Results: A 3-year-and-10-month-old male with no remarkable past or family medical history was admitted due to "multiple skin ecchymoses". Initial management included transfusions of cryoprecipitate, hemocoagulase, and vitamin K. Although his coagulation parameters initially normalized, they later became aberrant again. Further testing of coagulation factor activity, lupus anticoagulant, anticardiolipin antibodies, and protein induced by vitamin K absence/antagonist-II (PIVKA-II) confirmed the diagnosis. Treatment with prothrombin complex concentrate and glucocorticoids led to gradual resolution of symptoms, signs, and laboratory abnormalities without recurrence. Conclusion: LAHPS should be considered in children presenting with multisite bleeding such as cutaneous bruising. With early diagnosis and timely intervention, the prognosis is generally favorable. PIVKA-II may serve as a valuable marker in the diagnosis and management of this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.